Granulocyte colony-stimulating factor (G-CSF) is generally not required for the management of CDK4/6 inhibitor-induced neutropenia, while a rapid neutropenia recovery is obtained by dose interruption and dose modification of the CDK4/6 inhibitor without modifying the endocrine agents. The gene discussed is CDK4; the disease is Decreased total neutrophil count.